PMC:7228307 / 52066-52502
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
---|---|---|---|---|---|---|
1044 | 342-346 | Gene | denotes | FcγR | Gene:2213 | |
1045 | 98-102 | Gene | denotes | FcγR | Gene:2213 | |
1046 | 50-54 | Gene | denotes | FcγR | Gene:2213 | |
1047 | 170-177 | Chemical | denotes | leucine | MESH:D007930 | |
1048 | 245-252 | Chemical | denotes | alanine | MESH:D000409 | |
1049 | 400-410 | Chemical | denotes | teplizumab | MESH:C502540 | |
1050 | 415-425 | Chemical | denotes | spesolimab | ||
1051 | 254-265 | Mutation | denotes | L234A L235A | p.L234,235A,A |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T404 | 23-33 | Body_part | denotes | amino acid | http://purl.org/sig/ont/fma/fma82739 |
T405 | 170-177 | Body_part | denotes | leucine | http://purl.org/sig/ont/fma/fma82757 |
T406 | 245-252 | Body_part | denotes | alanine | http://purl.org/sig/ont/fma/fma82749 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T880 | 20-22 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T881 | 50-52 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T882 | 98-100 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T883 | 112-113 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T884 | 224-228 | http://purl.obolibrary.org/obo/CLO_0007179 | denotes | L235 |
T885 | 342-344 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T68471 | 23-33 | Chemical | denotes | amino acid | http://purl.obolibrary.org/obo/CHEBI_33709 |
T62086 | 23-28 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T40175 | 29-33 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T80744 | 170-177 | Chemical | denotes | leucine | http://purl.obolibrary.org/obo/CHEBI_25017 |
T54623 | 245-252 | Chemical | denotes | alanine | http://purl.obolibrary.org/obo/CHEBI_16449 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T54 | 23-33 | Chemical | denotes | amino acid | http://purl.obolibrary.org/obo/CHEBI_33709 |
T55 | 170-177 | Chemical | denotes | leucine | http://purl.obolibrary.org/obo/CHEBI_25017 |
T56 | 245-252 | Chemical | denotes | alanine | http://purl.obolibrary.org/obo/CHEBI_16449 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
---|---|---|---|---|---|---|
1044 | 342-346 | Gene | denotes | FcγR | Gene:2213 | |
1045 | 98-102 | Gene | denotes | FcγR | Gene:2213 | |
1046 | 50-54 | Gene | denotes | FcγR | Gene:2213 | |
1047 | 170-177 | Chemical | denotes | leucine | MESH:D007930 | |
1048 | 245-252 | Chemical | denotes | alanine | MESH:D000409 | |
1049 | 400-410 | Chemical | denotes | teplizumab | MESH:C502540 | |
1050 | 415-425 | Chemical | denotes | spesolimab | ||
1051 | 254-265 | Mutation | denotes | L234A L235A | p.L234,235A,A |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T296 | 0-111 | Sentence | denotes | Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding. |
T297 | 112-267 | Sentence | denotes | A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A). |
T298 | 268-436 | Sentence | denotes | It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4). |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T403 | 23-33 | Body_part | denotes | amino acid | http://purl.org/sig/ont/fma/fma82739 |
T404 | 170-177 | Body_part | denotes | leucine | http://purl.org/sig/ont/fma/fma82757 |
T405 | 245-252 | Body_part | denotes | alanine | http://purl.org/sig/ont/fma/fma82749 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T296 | 0-111 | Sentence | denotes | Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding. |
T297 | 112-267 | Sentence | denotes | A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A). |
T298 | 268-436 | Sentence | denotes | It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4). |